ORIENTAL: ORantinib InvEstigatioN on TAce combination triaL

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Of TSU-68 In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221317

Enrollment

880

Registered

2010-11-26

Start date

2010-11-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

investigational material(s) Generic name etc : TSU-68 INN of investigational material : orantinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients must be diagnosed as HCC. 2)Patients has no indications for treatment with curative hepatic resection or curative percutaneous local therapy. 3)Eastern Cooperetive Oncology Group (ECOG) performance status (PS) of 0 or 1. 4)Patients is able to receive oral medication.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Overall Survival	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026